3month10 - 12day, the60The China International Beauty Expo and the 4th International Medical and Health Expo were held in Guangzhou, China. During the same period, the 2nd Global Assisted Reproduction Exchange Conference was successfully organized. With the theme of 'Insight into the Future & Business Empowerment & Shared Opportunities', experts and scholars in the industry, reproductive peers, and heads of global reproductive institutions were invited to discuss policy trends and market prospects with the audience at the event, contributing to the accelerated development of the assisted reproductive industry.
Frost & SullivanFrost & SullivanLiu Weiqi, Director of Healthcare Industry Consulting for Greater China at Frost & Sullivan (referred to as 'Frost & Sullivan'), was invited to attend the conference and delivered a keynote speech titled 'Assisted Reproductive Technologies at the Forefront, Drawing a Market Blueprint for the Reproductive Health Testing Industry'. He also provided an in-depth interpretation of the 'White Paper on the Current Industry Situation and Future Development of China's Assisted Reproductive Industry'.
Frost & Sullivan's Healthcare Industry Consulting Director for Greater China Liu Weiqi
According to Liu Weiqi, In vitro fertilization technologyIVF) is currently the most effective assisted reproductive technology for treating infertility or genetic problems. Its core technology has undergone three development iterations and has now evolved to Preimplantation genetic testingPGT) Genetic testing can be conducted on embryos before implantation to screen for healthy embryos for transplantation, thereby reducing genetic risks.
很抱歉，我还未学习到如何回答这个问题的内容，暂时无法提供相关信息。
The assisted reproductive industry is composed of a series of participants centered around assisted reproductive technology, which can be divided into upstream and downstream segments. The upstream includes reproductive health testing, while the downstream involves the implementation of assisted reproductive treatments.
Source: Frost & Sullivan report
Liu Weiqi stated that the supply and demand in the assisted reproductive industry are currently uneven, and there is an urgent need for the development of assisted reproductive technology.
From the demand side, The number of births in China has declined for four consecutive years, the prevalence of infertility continues to rise, and the number of infertile couples is increasing year by year.2021Year achieved5,230ten thousand pairs; From the supply side, There is a serious regional imbalance in the overall distribution of national assisted reproductive institutions, and the number of institutions approved to carry out third-generation assisted reproduction is small. As of2021year12month31day, only78The home medical institution has been approved to carry out the third-generation technology with qualificationsPGT.
Source: Frost & Sullivan report
But from a policy perspective, 2001Since the beginning of this year, regulatory oversight in the assisted reproductive industry has become more standardized. The National Healthcare Security Administration has gradually included some assisted reproductive technology projects within the scope of medical insurance fund payments. Favorable policies are expected to benefit the development of the assisted reproductive industry.
Source: Frost & Sullivan report
Liu Weiqi pointed out that, driven by multiple factors such as the continuous increase in China's demand for assisted reproduction and technological improvements, the gap in the penetration rate of assisted reproductive technology between China and developed countries is gradually narrowing. Moreover, due to the huge patient population in the Chinese market, the overall number of people receiving assisted reproduction is still higher than that in the United States and Europe. At the same time, since there is still room for growth in China's penetration rate, it can be seen that the market potential of this industry is enormous.
Source: Frost & Sullivan report
Subsequently, Liu Weiqi briefly analyzed the reproductive health testing industry. The main current reproductive health monitoring items include ultrasound examinations and fetal magnetic resonance imaging.MRISerum endocrine hormone testing, genetic testing, and chromosome karyotype testing, etc. According to Frost & Sullivan research, Traditional reproductive health testing technologies in China are less precise. However, with continuous technological iteration, reproductive health testing has become digital and intelligent, with efficiency continuously improving. In the future, chromosome testing and genetic testing technologies are expected to be further popularized.
Source: Frost & Sullivan report
Liu Weiqi stated that reproductive health testing is of great significance not only for individuals and families planning to conceive but also for the entire society (the entire working-age population). The potential market for reproductive health testing includes not only the examination and treatment of infertile patients but also extends to routine testing for reproductive health and genetic risks among the entire reproductive age population. The market prospects for reproductive health testing in China are broad.
Source: Frost & Sullivan report
"At the same time, favorable industry policies, continuous improvement in assisted reproductive technology, localization of the industrial chain, and increased patient willingness to pay will boost the further development of the reproductive health testing industry," said Liu Weiqi.
Recommended Reading
↓↓Long-press to scan the QR code below to obtain ↓↓
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content and promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
